Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15801114 | 1.00 | MAPT (0.71) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL9531913 | 0.92 | NPC1 (0.68) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL336009 | 0.92 | NPC1 (0.65) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL15156349 | 0.91 | MAPT (0.62) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL909633 | 0.91 | MAPT (0.62) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL11207169 | 0.90 | MAPT (0.61) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL26356999 | 0.90 | MAPT (0.61) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL1483566 | 0.90 | MAPT (0.71) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL1372140 | 0.90 | MAPT (0.66) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL13070319 | 0.90 | NPC1 (0.61) | MAPTALDH1A1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076941-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | UNIV GEORGETOWN (US) | 2026-03-19 | — | — | US | disclosed |
| EP-3204376-B1 | INDOLINONE COMPOUNDS AND USES THEREOF | ONCTERNAL THERAPEUTICS INC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20220288023-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2022-09-15 | — | — | US | disclosed |
| US-20180256546-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2018-09-13 | — | — | US | disclosed |
| US-9987251-B2 | Indolinone compounds and uses thereof | Oncternal Therapeutics, Inc. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9987251-B2 | Indolinone compounds and uses thereof | Oncternal Therapeutics, Inc. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9987251-B2 | Indolinone compounds and uses thereof | Oncternal Therapeutics, Inc. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9895352-B2 | Indolinone compounds and uses thereof | Oncternal Therapeutics, Inc. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9895352-B2 | Indolinone compounds and uses thereof | Oncternal Therapeutics, Inc. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9895352-B2 | Indolinone compounds and uses thereof | Oncternal Therapeutics, Inc. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170066720-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2017-03-09 | — | — | US | disclosed |
| US-20170066720-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2017-03-09 | — | — | US | disclosed |
| US-20170066720-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2017-03-09 | — | — | US | disclosed |
| US-20170065559-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2017-03-09 | — | — | US | disclosed |
| US-20170065559-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2017-03-09 | — | — | US | disclosed |
| US-20170065559-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2017-03-09 | — | — | US | disclosed |
| WO-2016057698-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | Tokalas, Inc. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160102055-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2016-04-14 | — | — | US | disclosed |
| US-20160102055-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2016-04-14 | — | — | US | disclosed |
| US-20160102055-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066720-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | FLI1, EWSR1, IKZF1 | MAPT 3179/4885ALDH1A1 1699/4885KMT2A 1097/4885 |
| US-20160102055-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | FLI1, EWSR1, IKZF1 | MAPT 3179/4885ALDH1A1 1699/4885KMT2A 1097/4885 |
| US-20260076941-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | FLI1, EWSR1, HNRNPH3 | MAPT 4588/4885ALDH1A1 1749/4885KMT2A 1423/4885 |
| US-20220288023-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | FLI1, EWSR1, IKZF1 | MAPT 3179/4885ALDH1A1 1699/4885KMT2A 1097/4885 |
| US-20170065559-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | FLI1, EWSR1, IKZF1 | MAPT 3179/4885ALDH1A1 1699/4885KMT2A 1097/4885 |
| US-20180256546-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | FLI1, EWSR1, IKZF1 | MAPT 3179/4885ALDH1A1 1699/4885KMT2A 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.